New pill could stop early lung cancer from coming back
NCT ID NCT07330076
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This study tests a daily pill called iruplinalkib for people with early-stage (stage IA) ALK-positive non-small cell lung cancer who have high-risk factors. After surgery to remove the tumor, participants take the pill for up to three years to see if it helps keep the cancer from returning. The trial involves 28 adults and is led by Tianjin Medical University Cancer Institute and Hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.